The past decade has transformed liquid biopsy, which was previously just an exciting concept, into a routine, commercially viable technology that is saving patients’ lives and transforming clinical trials.

Uniting the field in San Diego February 3-5, 2026 for 3 days of data- and strategy-driven presentations and networking sessions, the 10^th Liquid Biopsy for Precision Oncology Summit returns to deliver unparalleled insights, data, technology updates, and strategies spanning the entire drug development pipeline – from preclinical discovery, through clinical translation, to regulatory approval, reimbursement, and commercial adoption.

If you are working in precision oncology, or need enhanced insights into your patient population, optimized diagnostic and prognostic tools, or earlier detection of disease, this meeting should be considered a staple entry in your conference calendar. Across ctDNA, MRD, multi-omic biomarkers, and novel analytes, you will see how pharma are strategically integrating liquid biopsies into therapeutic pipelines, how diagnostic companies are designing more sensitive assays, and how the field is overcoming barriers to widespread clinical adoption.

• See the full event guide here: https://ter.li/nwkakw
• With free* tickets available for biopharma, visit the website to register: https://ter.li/2ewl2u

*Subject to terms and conditions